<DOC>
	<DOCNO>NCT01767610</DOCNO>
	<brief_summary>To develop combination product micronized fenofibrate plus pitavastatin , would like evaluate pharmacokinetic drug interaction compare steady-state pharmacokinetic characteristic arm repeat administrate Lipilfen cap . 160mg ( micronized fenofibrate 160mg ) Dae Woong Pharma . Livaro tab . 2mg ( pitavastatin Ca 2mg ) Joong Wae Pharm . 3 period separately combinedly .</brief_summary>
	<brief_title>Evaluation Pharmacokinetic Interaction Between Micronized Fenofibrate Pitavastatin</brief_title>
	<detailed_description />
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>1 . Years 2055 2 . Body weight≥50kg 18≤BMI≤29kg/m2 3 . Volunteer 1 . Subject serious active cardiovascular , respiratory , hepatology , renal , hematologic , gastrointestinal , immunologic , dermal , neurologic , psychological disease history disease 2 . Subject symptom acute disease within 28days prior study medication dose 3 . Subject known history affect absorption , distribution , metabolism excretion drug 4 . Subject clinically significant active chronic disease 5 . Subject follow condition laboratory test i. AST ( aspartate aminotransferase ) ALT ( alanine transferase ) &gt; upper normal limit × 1.5 ii . Total bilirubin &gt; upper normal limit × 1.5 iii . renal failure Creatinine clearance &lt; 50mL/min iv . creatine phosphokinase &gt; upper normal limit × 2 6 . Positive test result hepatitis B virus surface antigen , antihepatitis C virus antibody , venereal disease research laboratory test 7 . Use prescription medication within 14 day prior study medication dose 8 . Use medication overthecounter medication include oriental medication within 7 day prior study medication dose 9 . Subject clinically significant allergic disease ( except mild allergic rhinitis mild allergic dermatitis need administer drug ) 10 . Subject know hypersensitivity reaction fenofibrate , fenofibric acid statin 11. gallbladder disease 12 . Subject experience photoallergy phototoxicity administrate fibrates ketoprofen 13 . Subject genetic deficiency galactose intolerance , Lapp lactose deficiency glucosegalactose malabsorption 14 . Subject albe take institutional standard meal 15 . Subject whole blood donation within 60days , component blood donation within 20days 16 . Subjects receive blood transfusion within 30days prior study medication dose 17 . Participation clinical investigation within 60days prior study medication dose 18 . Continued excessive use caffeine ( caffeine &gt; five cups/day ) , alcohol ( alcohol &gt; 30g/day ) severe heavy smoker ( cigarette &gt; 10 cigarette per day ) 19 . Subjects decision nonparticipation investigator 's review due laboratory test result excuse nonresponding request instruction investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>